Omlonti is owned by Santen.
Omlonti contains Omidenepag Isopropyl.
Omlonti has a total of 9 drug patents out of which 0 drug patents have expired.
Omlonti was authorised for market use on 22 September, 2022.
Omlonti is available in solution;ophthalmic dosage forms.
Omlonti can be used as method of treating open-angle glaucoma or ocular hypertension in patients.
Drug patent challenges can be filed against Omlonti from 2026-09-22.
The generics of Omlonti are possible to be released after 10 June, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8648097 | SANTEN | Pyridylaminoacetic acid compound |
Oct, 2029
(6 years from now) | |
US10774072 | SANTEN | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685986 | SANTEN | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(6 years from now) | |
US10765750 | SANTEN | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US11197849 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US9415038 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
USRE48183 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US10702511 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US10179127 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 2026-09-22
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
21
Japan
19
United States
7
China
7
European Union
6
Spain
5
Canada
5
Korea, Republic of
4
Australia
3
Hong Kong
3
Denmark
3
Poland
3
Portugal
3
Mexico
3
Hungary
2
Philippines
2
Malaysia
2
Turkey
2
Brazil
2
Singapore
2
EA
2
New Zealand
2
Croatia
2
Cyprus
2
Israel
2
Taiwan
2
Georgia
2
Slovenia
1
Ukraine
1
San Marino
1
Chile
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic